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effective in pts progressing on G (Viswanathan A et al, Lung Cancer 
2005). Aim of this study was the evaluation of response and time to 
progression (TTP) in advanced NSCLC pts treated with G after failure 
of E.
Methods: Pts received G 250 mg/day after disease progression (PD) 
with E 150 mg/day. Pts accrual was stopped on August 2006 after the 
approval of E for use in Italy and the consequent closure of the G com-
passionate-use program. 
Results: From May 2005 to August 2006, 15 pts were enrolled. Median 
age 65 years (50-85); males= 14 pts (93%); never/former smokers= 
4/10 pts (26/67%); adenocarcinoma= 10 pts (67%); PS 0/1= 5/10 pts 
(33/67%); in 2 pts (13%) E was administered as ﬁrst-line therapy, 8 pts 
(53%) received 2 prior lines of chemotherapy (CT) and 3 pts (20%) 
received CT between E and G. One patient (7%) had a partial response 
(PR) and 5 pts (33%) had disease stabilization (SD) with E; with G no 
PR and 6 SD (40%) were obtained. Five out of 6 RP/SD pts with E, had 
SD with G; 8 out of 9 PD pts with E, had PD with G; 1 SD patient with 
E, progressed with G and 1 vice versa. TTP in RP/SD pts was 7.2 and 
3.4 months for E and G respectively; in PD pts TTP was 1.7 and 1.6 for 
E and G respectively.
Conclusions: Our data suggest that there is a beneﬁt with G in pts who 
had RP/SD with E and that is associated with a good TTP. Conversely 
G is not recommended in pts that immediately progressed after E. An 
analysis of the role of mutational status and other biomarkers in pre-
dicting clinical outcome is currently underway.
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Background: One retrospective study (Hotta K, Ann Oncol 2005), in-
vestigating the prognosis of patients (pts) obtaining SD as best response 
with G treatment, has demonstrated that both progression-free survival 
(PFS) and survival (S) were signiﬁcantly longer than those in pts with 
progressive disease (PD). The aim of this retrospective study was to 
compare the PFS and S outcome in pts with advanced NSCLC who 
achieved SD or partial response (PR) after treatment with E or G.
Methods: Pooled data from 62 pts, entered into an expanded access 
program of E (n=31) and a compassionate-use program of G (n=31), 
were retrospectively analyzed. E and G were given orally at 150 and 
250 mg per day respectively and were continued until disease progres-
sion, development of unacceptable toxicity or patient’s refusal.
Results: Pts characteristics: median age 69 years (42-85); females= 
21 pts (34%); never/former smokers= 16/38 pts (26/61%); adenocar-
cinoma/BAC= 35/10 pts (56/16%); PS 0/1= 18/38 pts (29/61%). In 16 
pts (26%) E or G were given as ﬁrst-line therapy; 21 pts (34%) had 
received ≥2 prior lines of chemotherapy. Six pts (10%) achieved a PR 
and 18 pts (29%) obtained SD. TTP and OS in pts obtaining PR and 
SD were comparable: 7 vs 5.5 and 9.7 vs 9.1 months respectively. In 
progressing pts median TTP and OS were 1.7 and 3.7 months. No dif-
ference in response, TTP and S between E and G were demonstrated.
Conclusions: Our ﬁndings indicate the importance of achieving disease 
control with both E and G treatment. Pts obtaining SD with E or G had 
a similar PFS and S compared with those having PR. 
An analysis of the role of mutational status and other biomarkers in 
predicting clinical outcome is currently underway.
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Background: BIBF 1120 is a highly potent, orally bioavailable triple 
angiokinase inhibitor (VEGFRs, PDGRs, FGFRs) that suppresses tu-
mor growth through mechanisms inhibiting tumor neovascularization. 
Pemetrexed is an antifolate agent that inhibits de novo DNA synthesis 
pathways and has demonstrated clinical beneﬁt in advanced or meta-
static NSCLC after prior ﬁrst line chemotherapy. 
This Phase I, open-label dose escalation study investigated the combi-
nation of BIBF 1120 together with pemetrexed in previously treated pa-
tients with recurrent advanced stage NSCLC. The potential additive or 
synergistic effects of novel therapeutic regimens may make combina-
tions of these agents particularly attractive for the treatment of patients 
with recurrent NSCLC compared to a single agent alone.
The primary objectives of this trial were to determine the safety, toler-
ability, and maximum tolerated dose (MTD) of BIBF 1120 in combina-
tion with pemetrexed.
Methods: Patients with advanced stage NSCLC, PS 0-1, previously 
treated with one ﬁrst line platinum-based chemotherapy regimen were 
eligible for this trial. The trial was an open label, dose escalation design 
with BIBF 1120 at a starting dose of 100 mg bid, taken on days 2-21, 
combined with standard dose pemetrexed (500 mg/m2) given as a 10 
minute intravenous infusion on day 1 of a 21 day cycle. Patients could 
be treated for a minimum of four and a maximum of six cycles of 
the combination therapy, with an option of BIBF 1120 monotherapy 
following the completion of the combination stage. BIBF 1120 was 
escalated at doses of 50 mg per cohort until the MTD dose was deter-
mined. The MTD was deﬁned as the dose of BIBF 1120 which was one 
dose cohort below the dose at which two or more out of six patients 
experienced dose limiting toxicity (DLT) in the ﬁrst treatment cycle. 
Tumor assessments were performed at screening and after every second 
treatment cycle according to RECIST.
Results: Twenty-six patients (13 male, 13 female) in total and 12 at 
the MTD were treated in this study. The MTD dose of BIBF 1120 was 
determined to be 200 mg bid in combination with standard dose peme-
trexed. Generally the combination of BIBF 1120 and pemetrexed was 
well tolerated. A total of 17 DLT events (CTCAE Grade 3) occurred 
in the ﬁrst treatment cycle for all doses, including elevations in liver 
enzymes (3/17), fatigue (4/17), anorexia (2/17) and gastrointestinal 
disorders (6/17). These events resolved following discontinuation of 
the study medication. No Grade 4 events occurred in the study. Best 
responses by RECIST included (20 evaluable for response) 1 complete 
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response (CR), 2 partial responses (PR), and 8 patients with stable dis-
ease (SD). The patient with the CR has been maintained on BIBF 1120 
monotherapy for a period of over 52 weeks.
Conclusions: The combination of BIBF 1120 and pemetrexed in previ-
ously treated NSCLC patients was shown to be safe and well tolerated 
in this study. The MTD of BIBF 1120 was 200 mg bid when given with 
pemetrexed at 500 mg/m2. Signs of clinical efﬁcacy were observed in 
the small number of patients treated in this trial.
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Background: Advanced stage NSCLC patients (pts) with a PS of 2 
have inferior outcomes compared to good PS pts. No consensus exists 
on the most appropriate management approach, with options ranging 
from supportive care alone to platinum-based combination chemo-
therapy. SWOG has recently completed two trials (S0027) and (S0341) 
evaluating the value of sequential single agent chemotherapy and the 
EGFR tyrosine kinase inhibitor erlotinib (E) respectively in unselected 
pt populations with PS 2. This report details a comparative analysis of 
these two treatment approaches.
Methods: Eligibility: stage III B (pleural effusion)/IV NSCLC; PS 2; 
measurable disease (S0341), measurable + evaluable disease (S0027); 
no prior chemotherapy/biologic treatment. Pts > age 70 with PS 0-1 
also eligible for S0027 but this strata not included in this analysis. 
Treatment: (S0027) vinorelbine 25 mg/m2 d 1,8 q 21 d for 3 cycles then 
docetaxel 35 mg/m2 d1,8,15 q 28 d for 3 cycles; (S0341) E 150 mg 
orally daily.
Results: (S0027, S0341): Eligible patients: 42, 73; median age 73, 74; 
M/F (%) 55/45, 47/53; stage IIIB/IV (%) 15/85, 12/88, respectively. 
Response rate (RR), disease control rate{response + stable disease} 
(DCR), progression free survival (PFS), median survival (MST) and 
toxicity - see table.
Conclusions: Outcome with sequential single agent chemotherapy 
or single agent erlotinib remains poor in advanced NSCLC pts with 
PS 2. Overall tolerance of treatment appeared to be more favorable in 
pts receiving erlotinib. Better patient selection employing an EGFR 
biomarker strategy may improve results with E and result in a superior 
outcome to chemotherapy in this selected patient population. This 
concept is now being explored within SWOG.
S0027(N=42) S0341(N=73)
Response Rates:  
Complete/Partial 0%/11% (N=37) 1%/7% (N=72)
Disease Control Rate: 
Response+Stable Disease 38% (N=37) 43% (N=72)
PFS/MST (95% C I) 2.6(1.9-4.2)/ 5.5(3.1-6.5) 2.1(1.5-3.1)/ 5(3.5-7.3)
Grade 3/4 AE’s(%) 48/26 33/7
Grade 5 AE(%) 4.8 1.4
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Background: VAN (ZD6474) is an oral inhibitor of VEGFR, EGFR 
and RET. In a phase II trial, 181 patients with advanced NSCLC were 
randomized to 1st-line treatment with VAN, CP or VAN + CP. Progres-
sion free survival (PFS) was prolonged for VAN + CP vs CP (Heymach 
et al, Proc ASCO 2007). Exploratory subgroup analyses suggest gender 
differences in PFS beneﬁt for VAN + CP vs CP (HR 0.47 in females vs 
1.05 in males). We performed exploratory analyses of plasma levels of 
35 C/AFs to investigate gender differences and potential prognostic or 
predictive markers.
Methods: Plasma was collected at baseline (n = 123; VAN 55, CP 32, 
VAN + CP 36), day (D) 8 (n = 104), D22 (n = 95), and D43 (n = 83). 
We used multiplex bead assays to measure 33 plasma C/AFs, including 
VEGF, basic FGF, EGF, HGF, E-selectin, ICAM-1, MMP-9, multiple 
chemokines and interleukins (IL). Osteopontin and sVEGFR-2 were 
measured by ELISA. Cox models were applied on PFS to identify 
prognostic / predictive markers after rank transformation and adjusted 
for covariates.
Results: Signiﬁcant gender differences in baseline C/AF levels were 
seen for IL-15, IL-1RA, IL-2R, MIG, and MIP-1α (all higher in 
females, all p <.022). During treatment, signiﬁcant changes in median 
VEGF levels (102 pg/mL at baseline, 127 pg/mL at day 43, p = .041) 
and sVEGFR-2 levels (9593 pg/mL at baseline, 7696 pg/mL at day 43, 
p = .027) occurred in the VAN arm. IL-12, IL-1RA, MMP-9 and MCP-
1 levels were modulated in the CP and VCP arms. High baseline E-
selectin (p = .01), IL-6 (p = .018), and sIL-2R (p = .008) were negative 
prognostic indicators for PFS. Tests for treatment by factor interactions 
(assessing if treatment effect was different in patients with low and 
high levels of a factor), including all 3 treatment arms, were signiﬁcant 
for baseline HGF (p = .04) and sIL-2R (p = .008). Low levels of HGF 
and sIL-2R were predictive of prolonged PFS in the VAN arm, but not 
in the CP or VAN+CP arms. When only the VAN+CP and CP arms 
were considered, the tests for treatment by factor interaction were of 
borderline signiﬁcance for baseline ICAM-1, sVEGFR-2, MMP-9 and 
EGF. Low ICAM-1, sVEGFR-2, and MMP-9, and high EGF were as-
sociated with greater PFS in the VCP arm, but not in the CP arm. 
Conclusions: There are gender differences in PFS beneﬁt from VAN 
and in plasma C/AF proﬁle. Several C/AFs were of prognostic value, 
whereas low HGF and IL-2R were predictive of beneﬁt in the VAN 
but not CP and VAN + CP arms. This study suggests that broad-based 
plasma proﬁling of cytokines and angiogenic factors may be feasible 
approach for identifying prognostic and predictive markers of beneﬁt 
for different therapies. Further investigation of these biomarkers is 
warranted. 
